Physician profile
Mark Watkins
NPI 1972604692
$3,528.24
in general payments reported to CMS, 2019-2025
25 companies · $282 in 2025
The $282 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,006 · 2020: $303 · 2021: $431 · 2022: $562 · 2023: $438 · 2024: $506 · 2025: $282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,226.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $669.99 | 2019-2025 | Repatha, Repatha |
| Gilead Sciences, INC. | $409.51 | 2023-2024 | |
| Medtronic Vascular, INC. | $318.71 | 2019-2020 | |
| Shockwave Medical, INC | $285.15 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $267.93 | 2019-2021 | |
| Astellas Pharma US INC | $222.99 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $162.01 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $156.43 | 2019-2025 | Wainua |
| Boston Scientific Corporation | $149.97 | 2022 | |
| Medtronic, INC. | $132.57 | 2021-2025 | Complete Se Vascular, Micra, Mycarelink |
| E.R. Squibb & Sons, L.L.C. | $125.01 | 2019-2023 | Camzyos |
| Biosense Webster, INC. | $125.00 | 2022 | |
| Abbott Laboratories | $107.11 | 2019-2022 | |
| Abiomed | $98.69 | 2024 | Impella |
| Cardinal Health 200 LLC | $69.54 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.39 | 2019-2021 | |
| Inari Medical, INC. | $37.92 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Regeneron Healthcare Solutions, INC. | $28.81 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $27.56 | 2020 | |
| Sanofi-Aventis U.S. LLC | $21.96 | 2019 | |
| Medtronic USA, INC. | $16.87 | 2019 | |
| Merck Sharp & Dohme LLC | $15.95 | 2021 | |
| Glaxosmithkline, LLC. | $15.80 | 2021 | |
| Esperion Therapeutics, INC. | $13.51 | 2021 | |
| Atricure, INC. | $10.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Watkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.